HOME >> MEDICINE >> NEWS
New data on the effect of Atacand(R) on NYHA class in a broad spectrum of heart failure patients

Mlndal, Sweden, 9 March 2004 Data presented today at the American College of Cardiology (ACC) annual meeting add weight to the evidence shown in the original publications from the CHARM* Programme of the effects of Atacand (candesartan cilexetil) in chronic heart failure (CHF) patients. The results from further analysis of the data add further support for the CHARM study as a landmark clinical research programme.

Importantly, one analysis1 found that New York Heart Association (NYHA) functional class improved in a broad spectrum of CHF patients treated with Atacand. Of all CHARM patients, 35.4% taking Atacand improved in NYHA functional class, 55.6% remained unchanged and 9% worsened. This compared with 32.5%, 57.5% and 10.3% respectively in the placebo group (p=0.004). These findings were supported by a favourable change in the Overall Treatment Evaluation in the Atacand group compared to the placebo group (p=0.01).

Commenting on this additional analysis, Professor John McMurray, principal investigator in the CHARM-Added study, Glasgow University and Western Infirmary, Glasgow, Scotland, said "Improving symptomatic well-being is a key objective of heart failure treatment. NYHA functional classification is the most widely used and validated measure of symptomatic limitation in CHF. That candesartan has been shown to improve NYHA functional class across the broad spectrum of CHF investigated in the CHARM Programme will have significant implications for clinical practice. These findings are consistent with a reduction in CHF hospitalisations".

A further analysis suggests that the development of atrial fibrillation (AF) in some patients with symptomatic chronic heart failure may also be reduced. Of the 7,601 heart failure patients in CHARM, 72.6% did not have atrial fibrillation (AF) at baseline. This new analysis found that, in the patients randomised to Atacand, new incidence of AF during the trial was 6.5%, compared to 7.9% in the place
'"/>

Contact: Mark Chamberlain
mark.chamberlain@ketchum.com
44-207-611-3649
Ketchum
9-Mar-2004


Page: 1 2

Related medicine news :

1. Strategy effective against drug resistant tuberculosis
2. Study shows patch therapy may be as effective as oral medications
3. Chronic pain treatments more effective when taken together, new study shows
4. Geodon effective in psychiatric emergencies; Sharply reduces time in restraints
5. Brain activity prior to treatment flags vulnerability to antidepressant side effects
6. Improving access to healthy food has little effect on diet
7. Storage time and temperature effects nutrients in spinach
8. Costs of antidepressants could have funded effective alternatives
9. New ways to design safer & more effective topical (transdermal) drug delivery announced in the PNAS
10. Government wasting your taxpayer money on ineffective drug cure
11. Neurobehavioral function during coma, stroke rehabilitation effective for elderly

Post Your Comments:
(Date:9/4/2015)... ... September 04, 2015 , ... Having access to a ... led to an increasing amount of unnecessary emergency room visits which affects hospitals’ abilities ... the country’s health bill. Fortunately, a solution to alleviate this problem has recently presented ...
(Date:9/4/2015)... ... 2015 , ... Lalonde Gordon ran a 44.64 seconds scorcher in the third ... men’s 400 meters final, with an impressive 44.89 seconds at the 2015 North American, ... Rica in August 2015. The 44.64 time is a new NACAC Championship record. ...
(Date:9/4/2015)... DC (PRWEB) , ... September 04, 2015 , ... ... they all pale in comparison to settlements under the Stark physician self-referral law. ... an upcoming Sept. 17 webinar from Atlantic Information Services, Inc. (AIS), will detail ...
(Date:9/4/2015)... NC (PRWEB) , ... September 04, 2015 , ... ... filtration products, has a Labor Day offer that cannot be passed up. ... stock up on necessary air and water filtration product replacements. Take advantage of ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... Friday night, ... IL hosting Generation Rescue’s A Night of Hope event supporting families affected by autism, ... and Rowena and Joe Salas, joined together at the Oscar Swan Inn to support ...
Breaking Medicine News(10 mins):Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2Health News:Jenny McCarthy & Donnie Wahlberg Help Raise Over $200,000 For Generation Rescue’s ‘Night Of Hope’ Chicago Charity Event 2
(Date:9/3/2015)... NEW YORK , Sept. 3, 2015 About ... in dryness of eyes due to deficient tear production ... This syndrome is of two types: aqueous tear deficient ... deficient dry eye, lacrimal glands do not produce enough ... eye. Meibomian glands secrete lipids to slow tear evaporation ...
(Date:9/3/2015)... Sept. 3, 2015  WellCare Health Plans, Inc. (NYSE: ... , senior vice president and chief financial officer, is ... Healthcare Conference on Wednesday, September 9, 2015, at 9:25 ... webcast live. In addition, a replay of the webcast ... broadcast. Both the live broadcast and the replay will ...
(Date:9/3/2015)... and ALISO VIEJO, Calif. ... (NYSE: AGN ), a leading global pharmaceutical ... medical device company focused on developing ocular implants ... today announced that they have entered into an ... an all-cash transaction.  Under the terms of the ...
Breaking Medicine Technology:Global Dry Eye Syndrome Market 2015-2019 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 3Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 4Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 5Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 6
Cached News: